Drug Information

Drug General Information
Drug ID
D0V9ZL
Former ID
DIB001394
Drug Name
FCE-28161
Synonyms
PNU-166945; Lodeca[3,4]benz[1,2-b]oxet-5-one; Copolymer of N-(2-hydroxypropyl)methacrylamide,methacryloylglycine 2-hydroxypropylamide and [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-6,12b-diacetoxy-9-[3-benza; Mido-2-(methacryloyl-glycyl-L-phenylalanyl-L-leucyl-glycyloxy)-3-phenylpropionyloxy]-12-benzoyloxy-4,11-dihydroxy-4a,8,13,13-tetramethyl-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyc
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Discontinued in Phase 1 [546352]
CAS Number
CAS 154330-65-1
Target and Pathway
Target(s) Tubulin Target Info Modulator [550854], [551871]
References
Ref 546352Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007669)
Ref 550854CN patent application no. 101065129, A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.